Alteration of DNA methyltransferases by eribulin elicits broad DNA methylation changes with potential therapeutic implications for triple-negative breast cancer.
Epigenomics
; 16(5): 293-308, 2024 Mar.
Article
em En
| MEDLINE
| ID: mdl-38356412
ABSTRACT
Background:
Triple-negative breast cancer (TNBC) is an aggressive disease with limited treatment options. Eribulin, a chemotherapeutic drug, induces epigenetic changes in cancer cells, suggesting a unique mechanism of action. Materials &methods:
MDA-MB 231 cells were treated with eribulin and paclitaxel, and the samples from 53 patients treated with neoadjuvant eribulin were compared with those from 14 patients who received the standard-of-care treatment using immunohistochemistry.Results:
Eribulin treatment caused significant DNA methylation changes in drug-tolerant persister TNBC cells, and it also elicited changes in the expression levels of epigenetic modifiers (DNMT1, TET1, DNMT3A/B) in vitro and in primary TNBC tumors.Conclusion:
These findings provide new insights into eribulin's mechanism of action and potential biomarkers for predicting TNBC treatment response.Palavras-chave
Texto completo:
1
Coleções:
01-internacional
Base de dados:
MEDLINE
Assunto principal:
Metilação de DNA
/
Neoplasias de Mama Triplo Negativas
/
Furanos
/
Policetídeos de Poliéter
Tipo de estudo:
Prognostic_studies
Limite:
Humans
Idioma:
En
Revista:
Epigenomics
Ano de publicação:
2024
Tipo de documento:
Article
País de afiliação:
Estados Unidos